WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 205599

CAS#: 1219951-09-3

Description: PTC299, a VEGF inhibitor, is an orally bioavailable, small molecule inhibitor of vascular endothelial growth factor (VEGF) synthesis with potential antiangiogenesis and antineoplastic activities. VEGF inhibitor PTC299 targets post-transcriptionally by selectively binding the 5'- and 3'-untranslated regions (UTR) of VEGF messenger RNA (mRNA), thereby preventing translation of VEGF. This inhibits VEGF protein production and decreases its levels in the tumor and bloodstream. In turn, this may result in the inhibition of migration, proliferation and survival of endothelial cells, microvessel formation, the inhibition of tumor cell proliferation, and eventually the induction of tumor cell death.

Chemical Structure

CAS# 1219951-09-3

Theoretical Analysis

MedKoo Cat#: 205599
Name: PTC299
CAS#: 1219951-09-3
Chemical Formula:
Exact Mass: 0.00
Molecular Weight: 0.000
Elemental Analysis:

Price and Availability

Size Price Availability Quantity
10mg USD -2
25mg USD -2
50mg USD -2
100mg USD -2
200mg USD -2
500mg USD -2
1g USD -1
2g USD -1
5g USD -1
Bulk inquiry

Synonym: PTC299; PTC 299; PTC-299.

IUPAC/Chemical Name: chemical structure is not available at this time.

InChi Key:

InChi Code:

SMILES Code: chemical structure is not available at this time.

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not soluble in water.

Shelf Life: >5 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:

More Info: PTC299 is currently being developed for the treatment of cancer. It has completed Phase 1a trials in healthy volunteers, and is now being studied in a Phase 1-2 trials in patients with solid tumors, metastatic breast cancer and neurofibromatosis type 2. PTC299 was designed to inhibit VEGF production in tumors. Because PTC299 inhibits VEGF production, its action occurs at a different point in the VEGF pathway than other therapies. PTC299 may be active both as a single agent or when used in combination with other anti-angiogenic agents or with chemotherapy agents for the treatment of cancers. (source:     

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 0.00 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Packer RJ, Rood BR, Turner DC, Stewart CF, Fisher M, Smith C, Young-Pouissant T, Goldman S, Lulla R, Banerjee A, Pollack I, Kun L, Onar-Thomas A, Wu S, Boyett JM, Fouladi M. Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study. J Neurooncol. 2015 Jan;121(1):217-24. doi: 0.1007/s11060-014-1665-1. Epub 2014 Nov 19. PubMed PMID: 25407389; PubMed Central PMCID: PMC4330963.

2: Fong B, Barkhoudarian G, Pezeshkian P, Parsa AT, Gopen Q, Yang I. The molecular biology and novel treatments of vestibular schwannomas. J Neurosurg. 2011 Nov;115(5):906-14. doi: 0.3171/2011.6.JNS11131. Epub 2011 Jul 29. Review. PubMed PMID: 21800959.